<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956446</url>
  </required_header>
  <id_info>
    <org_study_id>TBE-BB prospect</org_study_id>
    <nct_id>NCT03956446</nct_id>
  </id_info>
  <brief_title>Tick-borne Encephalitis and Borrelial Antibodies in Serum</brief_title>
  <official_title>Antibiotic Therapy for Patients With Tick-borne Encephalitis and Borrelial Antibodies in Serum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ljubljana School of Medicine, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Slovenia, tick-borne encephalitis and Lyme borreliosis are both endemic diseases with high
      incidence rates and they are both transmitted by a bite of infected Ixodes ricinus tick. In
      clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne
      encephalitis antibodies in serum of a patient with compatible clinical presentation and
      cerebrospinal pleocytosis. Patients with Lyme meningitis or meningoradiculitis also have
      cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not
      attest Lyme neuroborreliosis. Patients with tick-borne encephalitis and positive borrelial
      antibodies in serum, but not fulfilling criteria for Lyme neuroborreliosis, are often being
      treated with antibiotics in several European countries due to the possibility of double
      infection. The investigators hypothesise that such patients do not benefit from antibiotics.
      Such an approach may appear safe regarding the possibility of borrelial infection, however it
      can also be associated with detrimental consequences such as antibiotic related adverse
      reactions, negative epidemiological impact on bacterial resistance, and intravenous catheter
      related complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with objective manifestations of Lyme borreliosis</measure>
    <time_frame>one year</time_frame>
    <description>At each visit physical examination will be performed and clinical signs indicating objective manifestations of Lyme borreliosis, such as erythema migrans, will be searched for.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Tick Borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antibiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control. Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.</description>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symptomatic therapy</intervention_name>
    <description>Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
    <arm_group_label>No antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.</description>
    <arm_group_label>Doxycycline, Doxy®</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>No antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  clinical picture compatible with tick-borne encephalitis,

          -  clear cerebrospinal fluid,

          -  cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid &gt;5 x 106/)L,

          -  positive serum immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies against
             tick-borne encephalitis virus,

          -  positive serum IgG antibodies against Lyme borreliae.

        Exclusion Criteria:

          -  isolation of B.burgdorferi sensu lato from cerebrospinal fluid,

          -  positive intrathecal borrelial antibody production index,

          -  seroconversion of borrelial IgG antibodies,

          -  presence of erythema migrans and/or borrelial lymphocytoma in the last month,

          -  Bannwarth syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daša Stupica, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Centre Ljubljana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daša Stupica, MD PhD</last_name>
    <phone>+386 31 689324</phone>
    <email>dasa.stupica@kclj.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maša Velušček, MD</last_name>
    <phone>+38631332904</phone>
    <email>masa.veluscek@kclj.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daša Stupica, MD, PhD</last_name>
      <phone>+386 31 689 324</phone>
      <email>dasa.stupica@kclj.si</email>
    </contact>
    <contact_backup>
      <last_name>Maša Velušček, MD</last_name>
      <phone>+386 1 522 21 10</phone>
      <email>masa.veluscek@kclj.si</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Daša Stupica</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

